N/A
Manufactured by Spectra Medical Devices, LLC
13,967 FDA adverse event reports analyzed
Last updated: 2026-04-15
LIDOCAINE HYDROCHLORIDE ANHYDROUS is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Spectra Medical Devices, LLC. The most commonly reported adverse reactions for LIDOCAINE HYDROCHLORIDE ANHYDROUS include INFUSION SITE PAIN, NAUSEA, DRUG INEFFECTIVE, OFF LABEL USE, INFUSION SITE ERYTHEMA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for LIDOCAINE HYDROCHLORIDE ANHYDROUS.
Out of 6,009 classified reports for LIDOCAINE HYDROCHLORIDE ANHYDROUS:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 13,967 FDA FAERS reports that mention LIDOCAINE HYDROCHLORIDE ANHYDROUS. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include INFUSION SITE PAIN, NAUSEA, DRUG INEFFECTIVE, OFF LABEL USE, INFUSION SITE ERYTHEMA, DYSPNOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Spectra Medical Devices, LLC in connection with LIDOCAINE HYDROCHLORIDE ANHYDROUS. Always verify the specific product and NDC with your pharmacist.